News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
iECURE partners to develop next-generation liver-targeted lipid nanoparticles with Penn
iECURE announced that it has entered into an exclusive agreement with Penn to develop next-generation lipid nanoparticles (LNP) for liver gene editing applications.
Penn inventors named Heroes of the Year by Time Magazine
Drs. Katalin Kariko and Drew Weissman, inventors of the foundational RNA research that led to the COVID-19 vaccines, are two of researchers named by Time Magazine as their Heroes of the Year 2021.
Scout Bio licenses new Penn technology to help develop gene therapies for pets
Scout Bio, a Philadelphia company developing gene therapies for animal health, has licensed a new kind of technology from the Penn’s gene therapy program.
Passage Bio further expands Gene Therapy research partnership with Penn
Passage Bio has exercised two additional options for potential new drug candidates under its research collaboration with Penn's gene therapy program.
Cogwear and Rezon to make brain enhancing wearable for athletes
Strategic partnership combines the start-ups’ revolutionary technologies for brain injury reduction and cognitive performance
A chewing gum that could reduce SARS-CoV-2 transmission
In experiments using saliva samples from COVID-19 patients, the gum, which contains the ACE2 protein, neutralized the virus, according to research led by School of Dental Medicine scientists.
Celebration of Innovation 2021 Recap and Recording
The event honors the patent recipients from the previous fiscal year, as well as, those partners, inventors, and startups that made exceptional achievements.
Penn Center for Innovation reports largest number of annual patents in 2021
The Penn Center for Innovation had the most-ever patents issued for Penn and its affiliates this year, according to the center's 2021 Year in Review.
Developing a chewing gum to reduce the incidence of Covid-19
A chewing gum impregnated with a plant-grown protein can serve as a “trap” for the SARS-CoV-2 virus, reducing viral load in the chewers saliva and potentially tamping down transmission.
A record-breaking year for innovation
With its highest number of patents issued, commercial agreements, corporate-sponsored research funding, and licensing revenue receipts in a single period, PCI experienced a landmark fiscal year.